Position of the Transparency Council – Ocrevus (ocrelizumab)
At its meeting on 13 January 2025, the Transparency Council adopted position No. 6/2025 on the evaluation of the drug Ocrevus (ocrelizumab) under the drug program B.29 “Treatment of patients with multiple sclerosis (ICD-10: G35)”
Publication of the position >>